Medicover Integrated Clinical Services (MICS) is a specialised business unit within the Diagnostic Services division with the overarching objective to help bring innovative therapies and diagnostics to the market. MICS is focusing on clinical applications and clients from pharmaceuticals, diagnostics, biopharma, biotech, contract research organisations (CROs), biobanks, and other players within this attractive and exciting sector. We have been providing bespoke services to our clients and their patients for over 20 years, making strategic use of Medicover assets, including laboratories with state-of-the-art diagnostic equipment, medical clinics and hospitals, as well as the vast expertise and enthusiasm of a workforce that has grown to more than 20,000 professionals.
MICS’ services include and are organised along discrete lines of activity, including: Central Lab Services, Site Management Organisation, Precision Medicine and Companion Diagnostics. Tightly integrated in all Medicover geographies and beyond, MICS employs a dedicated team of highly specialised staff, including clinical and diagnostics specialists, contract research professionals, account managers, project managers, logistics experts, analysts, and more.
What We Do
Our activities support the entire spectrum of drug and therapy development activities starting from Biomarker Discovery to Market Launch. Our goal is to serve the needs of international life science partners wishing to tap into the expertise, professionalism, enthusiasm, and work ethic in Germany and Central Eastern Europe, by providing the utmost quality at a reasonable cost, leveraging flexible and innovative thinking, disciplined management, and significant economies of scale with an attractive cost base.
Why It Matters
We strive to make a difference in patients’ lives by helping bring innovative therapies and diagnostics to the market as a proud member of Medicover where Caring For Your Health is All We Do.
We believe in conducting all of our activities and services with the greatest attention to detail and with the overarching goal of making a difference in patients’ lives.
Why Us
The MICS business unit benefits from the full complement of all the latest equipment and methodologies employed by Medicover’s Healthcare and Diagnostics divisions and is therefore fully equipped and uniquely capable of taking on any challenge along the full spectrum of clinical development needs of the demanding life sciences, medical and pharmaceutical industry.
Central Lab Services
Our Central Lab Services (CLS) line coordinates every aspect of the laboratory part of a clinical trial, starting from sample collection at study sites, to resolution of data queries and final laboratory data submission. The CLS line provides comprehensive support services for pharmaceutical and biotechnological companies, including: kit preparation, logistics, extended analytical testing through our international network of over 100 Medicover / Synevo laboratories (many of which have been harmonised for clinical research purposes), sample processing and storage, data management, as well as project management and reporting.
Site Management Organisation
Our Site Management Organisation (SMO) are all about keeping up with the latest in medicine and working together to create new treatment methods. We cover clinical trials from phase I to IV, with a special focus on recruiting the right patients to each study. Our Medical Centers team up with specialists in various medical fields, expanding the range of research we conduct.
MICS engages Medicover clinics (>100 clinics) and clinical laboratories (>95), Medicover network partners (>2,500 clinics), and other clinical partners (>200 hospitals) to recruit patients. Our Diagnostic Services on-line channel currently reaches more than 2.1 million individuals per month, where we can engage patients interested in participating in clinical trials with targeted outreach programmes.
Precision Medicine
Our Precision Medicine (PM) service line integrates individual patient-level data from clinical records, diagnostic and molecular testing, as well as real-time monitoring, to provide an evidence-based foundation to examine the biological basis of disease especially relevant for clinical trials in oncology, immuno-oncology, and chronic as well as auto-immune diseases. We offer one of the most complete service portfolios in genetics, histopathology, and immunology which are applicable to clinical trials, and companion diagnostics development programmes. The opportunity for Medicover to be an instrumental commercialisation / market access partner in our core European markets should not be overlooked by life-science companies.
Companion Diagnostics
We provide companion diagnostics services for all stages of drug and therapy development programs within:
We offer companion diagnostics services covering all stages of drug and therapy development programs, encompassing biomarker discovery, target validation during early stages, custom assay development for later stages, and commercialization and regulatory support.
In biomarker discovery, we utilize techniques such as whole genome, whole exome, and targeted sequencing, alongside single-cell sequencing, genotyping, and gene expression analysis. With over 10 years of experience, we specialise in custom NGS assays known for their high sensitivity and specificity. Moreover, we provide commercialisation and regulatory support. We have the required legal, regulatory, and commercial expertise and experience to bring sponsors CDx assays to market in Europe.
For more information, please visit https://medicover-mics.com/